Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
481.9 USD | +1.56% |
|
+2.26% | +18.43% |
Jul. 02 | FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis | MT |
Jul. 02 | Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.43% | 124B | |
+19.81% | 114B | |
-23.74% | 19.42B | |
-18.24% | 16.2B | |
-19.97% | 15.31B | |
-49.33% | 14.19B | |
+57.08% | 14.32B | |
+7.95% | 14.31B | |
+126.04% | 11.29B | |
+156.70% | 9.71B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated, Q4 2012 Earnings Call, Jan 29, 2013